This article has been updated with comments from the company.
NEW YORK (GenomeWeb News) –Thermo Fisher Scientific said today that it has formed a scientific advisory board to support its relationships with healthcare companies and medical and research centers.
The company said that the SAB convened recently for an inaugural meeting that included President and CEO Marc Casper and Tyler Jacks, a member of the company's board of directors who also is director of the Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
In addition to Jacks, the newly-formed board's external members include Ronald Davis, of Stanford University's Department of Biochemistry; Steven Gygi, of Harvard Medical School's Department of Cell Biology; William Hahn, of Dana-Farber Cancer Institute's Department of Medical Oncology; and David Hillyard of the University of Utah's Department of Pathology.
"The insight and distinct expertise of each member of our scientific advisory board will be invaluable in helping us set a course for the innovation of new products and services that will meet the changing needs of our customers," Casper said in a statement.
Thermo Fisher Scientific said that it formed the board to "formalize the two-way exchange of technological information between the company and representatives from some of the world's premiere centers of health, science, and education."
Ron O'Brien, a spokesman for the company, told GenomeWeb Daily News today that although the firm has in the past had technical advisers in its various businesses, this board is "going to look across the spectrum of the entire company.
"I look at [the SAB] as a compass of sorts. If we're going through an evaluation process of a particular technology, this group will be able to provide direction," he explained.
"All of our businesses rely on the effort of the scientific community, both internal and external, but this is the first example of a corporate-wide scientific advisory board," he said.
"One of the things that we have been talking about recently is the company's scale and our depth of capability, and we're hoping that this scientific advisory board will help us to evaluate the benefits of that scale and depth in a way that will be visible through our innovation process," O'Brien added.